<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">93620</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Vospalitel'nye zabolevaniya organov malogo taza: prosto o slozhnom</article-title><trans-title-group xml:lang="ru"><trans-title>Воспалительные заболевания органов малого таза: просто о сложном</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sekhin</surname><given-names>S. V</given-names></name><name xml:lang="ru"><surname>Сехин</surname><given-names>С. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО Смоленская государственная медицинская академия Минздрава РФ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2012</year></pub-date><volume>14</volume><issue>6</issue><issue-title xml:lang="en">VOL 14, NO6 (2012)</issue-title><issue-title xml:lang="ru">ТОМ 14, №6 (2012)</issue-title><fpage>48</fpage><lpage>53</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/93620">https://consilium.orscience.ru/2075-1753/article/view/93620</self-uri><abstract xml:lang="ru"><p>Инфекции верхних отделов женского репродуктивного тракта являются одними из наиболее часто встречающихся инфекционных заболеваний у женщин детородного возраста. В настоящее время для обозначения данной патологии, как за рубежом, так и в России, широко используется термин «воспалительные заболевания органов малого таза» (ВЗОМТ). К ним относятся эндометрит, сальпингит, тубоовариальный абсцесс и пельвиоперитонит как по отдельности, так и в сочетании. Также часто встречается термин «хронические ВЗОМТ», однако он не совсем корректен, так как по сути ВЗОМТ – это всегда острый процесс с более или менее выраженной клинической симптоматикой. То, что подразумевают под «хроническими» эндометритами, сальпингитами и пр., как правило, является последствием перенесенного острого воспалительного процесса в виде спаек, образования рубцов и непроходимости маточных труб. Большие проблемы малого таза Помимо прямых экономических затрат при ВЗОМТ в виде временной нетрудоспособности, расходов на диагностику, лечение и реабилитацию, указанная патология приводит к серьезным негативным последствиям для репродуктивного здоровья.Лечение и реабилитация пациенток с подобными осложнениями не бывают быстрыми и не всегда дают положительный результат, а для восстановления репродуктивной функции зачастую требуются вспомогательные репродуктивные технологии (экстракорпоральное оплодотворение). Стоимость этих мероприятий может в несколько раз превышать стоимость лечения первичного эпизода ВЗОМТ.Все это дает основание отнести инфекции органов малого таза к социально значимым заболеваниям, своевременная диагностика и эффективное лечение которых позволяют снизить негативное воздействие на репродуктивное здоровье и сократить расходы как государственной системы здравоохранения, так и личные затраты пациенток.</p></abstract></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Sweet R.L., Gibbs R.S. Pelvic inflammatory disease. In: Infectious diseases of female genital tract. Philadelphia: Lippincott Williams &amp; Wilkins, 2009; p. 220–44.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morbidity and Mortality Weekly Report 2010; 59 (RR-12): 110.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Westrom L.V. Sexually transmitted diseases and infertility. Sexually Transmitted Diseases 1994; 21 (Suppl.): 532–7.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Westrom L.V., Joesoef R, Reynolds G et al. Pelvic inflammatory disease and infertility. A cohort study of 1844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sexually Transmitted Diseases 1992; 19: 185–92.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Westrom L.V., Berger G.S. Consequences of pelvic inflammatory disease. Pelvic inflammatory disease. New York: Raven Press, 1992; p. 101–14.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Hillis S.D., Joesoef R, Marchbanks P.A. et al. Delayed care of pelvic inflammatory disease is a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 168: 1503–9.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ross J, Judlin P, Nilas L. European guideline for the management of pelvic inﬂammatory disease. Int J STD AIDS 2007; 18: 662–6.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sweet R.L. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ness R.B., Soper D.E., Holley R.L. et al. Eﬀectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the pelvic inflammatory disease evaluation and clinical health (PEACH) randomized trial. Am J Obstet Gynecol 2002; 186 (5): 929–37.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Manhart L.E., Critchlow C.W., Holmes K.K. et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis 2003; 187 (4): 650–7.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Pépin J, Labbé A.C., Khonde N et al. Mycoplasma qenitalium: an organism commonly associated with cervicitis among west African sex workers. Sex Transmit Infect 2005; 81 (1): 67–72.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Moller B.R., Taylor-Robinson D, Furr P.M., Freundt E.A. Acute upper genital - tract disease in female monkeys provoked experimentally by Mycoplasma genitalium. Br J Experiment Pathology 1985; 66 (4): 417–26.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Barzynska A, Funch P, Fedder J et al. Morphology of human Fallopian tubes after infection with Mycoplasma genitalium and Mycoplasma hominis: In vitro organ culture study. Hum Reprod 2007; 22 (4): 968–79.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. Смоленск: МАКМАХ, 2007.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40 (5): 639–51.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Aldridge K.E., Ashcraft D.S. et al. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemotherapy 1997; 41 (3): 709–11.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Woodcock J.M., Andrews J.M., Boswell F.J. et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemotherapy 1997; 41: 101–6.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Dalhoff A. In vitro activities of quinolones. Expert opinion on investigational drugs 1999; 8 (2); 123–37.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bebear C.M., de Barbeyrac B, Pereyre S et al. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14 (8): 801–5.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Sullivan J.T., Woodruff M, Lettieri J et al. Pharmacokinetics of a once - daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemotherapy 1999; 43 (11): 2793–7.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102 (2): 132–6.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Ross J.D., Cronje H.S., Paszkowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transmitd Infect 2006; 82 (6): 446–51.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Heystek M, Ross J.D., PID Study Group. A randomized double - blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Internat J STD AIDS 2009; 20 (10): 690–5.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG: Int J Obstet Gynaecol 2010; 117 (12): 1475–84.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Mu Y, Huang J, Liu R et al. Efficacy and safety profile of moxifloxacin in treatment of urogenital system infections: A meta - analysis of randomized controlled trials. African J Pharmacy Pharmacol 2012; 6 (26): 1910–22.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Walker C.K., Sweet R.L. Management. In: Sweet R.L., Wiesenfeld H.C. editors. Pelvic Inflammatory Disease. London: Taylor &amp; Francis, 2006; p. 141–56.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Ross J, Mc Carthy G. UK National Guideline for the management of Pelvic Inflammatory Disease 2011. British Association for Sexual Health and HIV, 2011. www.bashh.org/documents/3205.</mixed-citation></ref></ref-list></back></article>
